Highly potent nociceptin analog containing the Arg-Lys triple repeat

被引:71
作者
Okada, K
Sujaku, T
Chuman, Y
Nakashima, R
Nose, T
Costa, T
Yamada, Y
Yokoyama, M
Nagahisa, A
Shimohigashi, Y [1 ]
机构
[1] Kyushu Univ, Fac & Grad Sch Sci, Dept Chem, Lab Struct Funct Biochem, Fukuoka 8128581, Japan
[2] Pfizer Pharmaceut Inc, Cent Res, Aichi 4702393, Japan
[3] Ist Super Sanita, Farmacol Lab, I-00161 Rome, Italy
关键词
nociceptin; nociceptive peptides; opioid peptides; opioid receptors; structure-activity studies; receptor binding;
D O I
10.1006/bbrc.2000.3822
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
One of the structural characteristics of a neuropeptide nociceptin is the existence of Arg-Lys (RK) residues at positions 8-9 and 12-13; both RKs have been suggested to bind to the acidic amino acid cluster in the second extracellular loop of the seven transmembrane domain receptor ORL1. With a design strategy of attempting to obtain an analog that binds moire strongly to the receptor's acidic cluster, we synthesized a series of nociceptin analogs in which the RK dipeptide unit was placed at positions 6-7, 10-11, or 14-15 adjacent to the parent RKs. Among these nociceptin analogs containing the RK triple repeat, [Arg-Lys(6-7)]. and [Arg-Lys(10-11)]nociceptins exhibited weak activities (6-9 and 60-90% of nociceptin, respectively) both in the receptor binding assay and in the [S-35]GTP gammaS binding functional assay. In contrast, [Arg-Lys(14-15)]nociceptin was found to be very potent in both assays (3-fold in binding and 17-fold in GTP gammaS functional assay). [Arg-Lys(14-15)]nociceptin was the first peptide analog found to be stronger than the parent nociceptin, and structure-activity studies have suggested that the incorporated Arg-Lys(14-15) interacts with either the receptor acidic amino acid cluster or the receptor aromatic aminoacidresidues. (C) 2000 Academic Press.
引用
收藏
页码:493 / 498
页数:6
相关论文
共 42 条
[11]  
Dooley CT, 1997, J PHARMACOL EXP THER, V283, P735
[12]   Pharmacological analysis of dopamine stimulation of [S-35]-GTP gamma S binding via human D-2short and D-2long dopamine receptors expressed in recombinant cells [J].
Gardner, B ;
Hall, DA ;
Strange, PG .
BRITISH JOURNAL OF PHARMACOLOGY, 1996, 118 (06) :1544-1550
[13]   PORCINE PITUITARY DYNORPHIN - COMPLETE AMINO-ACID-SEQUENCE OF THE BIOLOGICALLY-ACTIVE HEPTADECAPEPTIDE [J].
GOLDSTEIN, A ;
FISCHLI, W ;
LOWNEY, LI ;
HUNKAPILLER, M ;
HOOD, L .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1981, 78 (11) :7219-7223
[14]  
KING DS, 1990, INT J PEPT PROT RES, V36, P255
[15]   Comparison of the structure-activity relationships of nociceptin and dynorphin A using chimeric peptides [J].
Lapalu, S ;
Moisand, C ;
Mazarguil, H ;
Cambois, G ;
Mollereau, C ;
Meunier, JC .
FEBS LETTERS, 1997, 417 (03) :333-336
[16]   PHARMACOLOGICAL CHARACTERIZATION OF ACETYLCHOLINE-STIMULATED [S-35] GTP-GAMMA-S BINDING MEDIATED BY HUMAN MUSCARINIC M1-M4 RECEPTORS - ANTAGONIST STUDIES [J].
LAZARENO, S ;
BIRDSALL, NJM .
BRITISH JOURNAL OF PHARMACOLOGY, 1993, 109 (04) :1120-1127
[17]  
LORENZEN A, 1993, MOL PHARMACOL, V44, P115
[18]   Facilitation of long-term potentiation and memory in mice lacking nociception receptors [J].
Manabe, T ;
Noda, Y ;
Mamiya, T ;
Katagiri, H ;
Houtani, T ;
Nishi, M ;
Noda, T ;
Takahashi, T ;
Sugimoto, T ;
Nabeshima, T ;
Takeshima, H .
NATURE, 1998, 394 (6693) :577-581
[19]   ISOLATION AND STRUCTURE OF THE ENDOGENOUS AGONIST OF OPIOID RECEPTOR-LIKE ORL(1) RECEPTOR [J].
MEUNIER, JC ;
MOLLEREAU, C ;
TOLL, L ;
SUAUDEAU, C ;
MOISAND, C ;
ALVINERIE, P ;
BUTOUR, JL ;
GUILLEMOT, JC ;
FERRARA, P ;
MONSARRAT, B ;
MAZARGUIL, H ;
VASSART, G ;
PARMENTIER, M ;
COSTENTIN, J .
NATURE, 1995, 377 (6549) :532-535
[20]   ORL1, A NOVEL MEMBER OF THE OPIOID RECEPTOR FAMILY - CLONING, FUNCTIONAL EXPRESSION AND LOCALIZATION [J].
MOLLEREAU, C ;
PARMENTIER, M ;
MAILLEUX, P ;
BUTOUR, JL ;
MOISAND, C ;
CHALON, P ;
CAPUT, D ;
VASSART, G ;
MEUNIER, JC .
FEBS LETTERS, 1994, 341 (01) :33-38